The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III ...

Waystar announced a new set of AI-powered tools designed to perform a variety of tasks, including appealing denied claims. 1 ...

Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...

San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder of UnitedHealth Group CEO Brian Thompson. In the wake of the murder ...

Blue Shield of California issued a statement regarding the devastating wildfires that have spread across large sections of the state. 1 While the combination of flames and winds continue to cause ...

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s. The two biggest stories in pharma in recent years have been the rise in popularity of GLP-1s and ...

Priority Review was based on results from the Phase III Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis. The FDA has granted Priority Review to a Biologics License ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

Acceptance of the Biologics License Application for subcutaneous Leqembi is based on results from the Clarity AD open-label ...